3 minutes someone in the
year approximately 700,000 people in the
heart disease and cancer, stroke is the third leading cause of death.
With about 5.7 million stroke survivors alive today – many of them
with permanent stroke-related disabilities – it is the leading cause of
disability in the
is estimated that in 2007, more than $62 billion will be spent on direct and
indirect costs related to stroke. The
mean lifetime cost of stroke in the
are limited treatment options for acute stroke.
is only one drug (Genentech’s Activase
tissue plasminogen activator - tPA) and one device (Concentric
Medical’s MERCI Retriever) cleared
by the FDA to treat acute ischemic stroke victims.
tPA is effective only when used within three hours of stroke onset and tPA is limited to less than 5% of stroke victims due to contraindications and risks, which include systemic or intracranial bleeding and controversies regarding its efficacy. In addition, tPA cannot be administered to the 120,000 stroke victims suffering from hemorrhagic stroke, which leaves those sufferers with no available treatment whatsoever.
Merci Retriever is a mechanical device that must physically be snaked to the
location of the clot and then engage the clot to remove it. It is
limited to larger vessels and is also ineffective in stroke
victims suffering from hemorrhagic stroke.
©2008 ReviveFlow, Inc. All rights reserved.